Objective To optimize decision making for anticoagulant treatment duration after incident
venous thromboembolism, we derived and internally validated two clinically applicable sex …

To optimize patient outcomes with anticoagulation for venous thromboembolism (VTE), it is
essential to assess patients for their recurrence risk. In this article, I will review the impact of …

After the first venous thromboembolism (VTE), anticoagulant treatment duration should be
based on the balance between the risk of recurrence and bleeding. However, this decision …

Background Although men are considered at high risk for recurrent venous
thromboembolism (VTE), sex-specific data on prognostic factors are lacking. We estimated …

Background Recurrent venous thromboembolism (VTE) is common. Current guidelines
suggest that patients with unprovoked VTE should continue anticoagulants unless they have …

Abstract Background and Aims Patients with unprovoked venous thromboembolism (VTE)
have a high recurrence risk, and guidelines suggest extended-phase anticoagulation. Many …

As arterial and venous thrombosis share common risk factors, a link between arterial and
venous thrombosis has been suggested recently. Therefore, we aimed to investigate the …

Background We aimed to validate and to refine current recurrent venous thromboembolism
(VTE) risk classification. Methods We performed a post hoc analysis of a multicentre cohort …

Introduction Prediction models for recurrence and bleeding are infrequently used when
deciding on anticoagulant treatment duration after venous thromboembolism (VTE) due to …

Venous thromboembolism (VTE) is a common and chronic disease with a considerable risk
of recurrence. Patients with unprovoked (in the absence of a transient risk factor) VTE have a …